somatuline p.r. 30 mg
medison pharma ltd - lanreotide acetate - powder and solvent for suspension for injection - lanreotide acetate 0.03 g/vial - lanreotide - lanreotide - treatment of acromegaly (when the treatment of growth hormone is not normalized after surgery and/or radiotherapy). treatment of the clinical symptoms of carcinoid tumors (after a test injection). treatment of primary thyrotropic adenomas responsible for hypethyroidism as a preparation for / or as a complement to surgery and/or radiotherapy or where these therapies are unsuitable.
somatuline autogel 60 mg
medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
somatuline autogel 90 mg
medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
somatuline autogel 120 mg
medison pharma ltd - lanreotide as acetate - solution for injection - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (gep-nets) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
somatuline autogel solution (extended release)
ipsen biopharmaceuticals canada inc - lanreotide (lanreotide acetate) - solution (extended release) - 60mg - lanreotide (lanreotide acetate) 60mg - other miscellaneous therapeutic agents
somatuline autogel solution (extended release)
ipsen biopharmaceuticals canada inc - lanreotide (lanreotide acetate) - solution (extended release) - 90mg - lanreotide (lanreotide acetate) 90mg - other miscellaneous therapeutic agents
somatuline autogel solution (extended release)
ipsen biopharmaceuticals canada inc - lanreotide (lanreotide acetate) - solution (extended release) - 120mg - lanreotide (lanreotide acetate) 120mg - other miscellaneous therapeutic agents
somatuline autogel 60mg/0.3ml solution for injection pre-filled syringes
ipsen ltd - lanreotide acetate - solution for injection - 200mg/1ml
somatuline autogel 90mg/0.3ml solution for injection pre-filled syringes
ipsen ltd - lanreotide acetate - solution for injection - 300mg/1ml
somatuline autogel 120mg/0.5ml solution for injection pre-filled syringes
ipsen ltd - lanreotide acetate - solution for injection - 240mg/1ml